^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CDK4 inhibitor

    Related drugs:
    3d
    ‌A Phase II, Two-Stage Study Evaluating the Efficacy of Entinostat in Combined with Fulvestrant in Locally Advanced or Metastatic Breast Cancer with Recurrence or Progression after CDK4/6 Inhibitor plus Endocrine Therapy (ChiCTR2500114131)
    P=N/A, N=50, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative
    |
    fulvestrant • Jingzhuda (entinostat)
    6d
    Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=28, Recruiting, The Methodist Hospital Research Institute | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Verzenio (abemaciclib) • fulvestrant
    8d
    DNACDKHR: CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment (clinicaltrials.gov)
    P2, N=158, Not yet recruiting, Peking University People's Hospital
    New P2 trial • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    11d
    To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negative Solid Tumor (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Atridia Pty Ltd.
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    fulvestrant • letrozole
    13d
    CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) (clinicaltrials.gov)
    P3, N=1903, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 amplification • PGR positive
    |
    tamoxifen • letrozole • exemestane
    18d
    postMONARCH: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (clinicaltrials.gov)
    P3, N=368, Active, not recruiting, Eli Lilly and Company | Trial completion date: Feb 2026 --> Dec 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant
    20d
    Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, University of Washington | Trial completion date: Sep 2027 --> Jul 2026 | Trial primary completion date: Sep 2026 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    Verzenio (abemaciclib)
    20d
    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P2/3, N=254, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    fulvestrant • SPH4336
    20d
    SIE-3: A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Palbociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Rovi Pharmaceuticals Laboratories
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Ibrance (palbociclib) • letrozole
    21d
    CAPItana: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain (clinicaltrials.gov)
    P3, N=101, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 negative
    |
    fulvestrant • Truqap (capivasertib)
    22d
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (clinicaltrials.gov)
    P1, N=136, Recruiting, Genentech, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    giredestrant (RG6171) • omeprazole
    28d
    BREAKER: Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: (clinicaltrials.gov)
    P=N/A, N=750, Recruiting, European Institute of Oncology | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative